Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43803

1.

Differences in adiposity and diet quality among individuals with inflammatory bowel disease in Eastern Canada.

DeClercq V, Langille MGI, Van Limbergen J.

PLoS One. 2018 Jul 19;13(7):e0200580. doi: 10.1371/journal.pone.0200580. eCollection 2018.

2.

Genistein induces macrophage polarization and systemic cytokine to ameliorate experimental colitis.

Abron JD, Singh NP, Price RL, Nagarkatti M, Nagarkatti PS, Singh UP.

PLoS One. 2018 Jul 19;13(7):e0199631. doi: 10.1371/journal.pone.0199631. eCollection 2018.

3.

A case of unusual histiocytic colitis in a chronic alcoholic obese patient with ankylosing spondylitis.

Guerra Diaz N, Sempoux C, Jouret-Mourin A, de Burbure C, Druez P.

Acta Gastroenterol Belg. 2018 Apr-Jun;81(2):327-329.

PMID:
30024706
4.

Advances in understanding the role of cytokines in inflammatory bowel disease.

Bevivino G, Monteleone G.

Expert Rev Gastroenterol Hepatol. 2018 Jul 19. doi: 10.1080/17474124.2018.1503053. [Epub ahead of print]

PMID:
30024302
5.

A Patient with Ulcerative Colitis Complicated by Systemic Vein Thrombosis.

Meštrović A, Žaja I, Ardalić Ž, Vrebalov-Cindro P, Šustić I, Puljiz M, Bratanić A, Bonacin D.

Case Rep Gastroenterol. 2018 Jun 25;12(2):322-326. doi: 10.1159/000488191. eCollection 2018 May-Aug.

PMID:
30022923
6.

[Pyoderma Gangrenosum in a Patient with Ulcerative Colitis].

Valejo Coelho MM, Fernandes C.

Acta Med Port. 2018 Jun 29;31(6):346. doi: 10.20344/amp.10641. Epub 2018 Jun 29. Portuguese. No abstract available.

PMID:
30020881
7.

Molecular Mechanisms of Somatostatin-Mediated Intestinal Epithelial Barrier Function Restoration by Upregulating Claudin-4 in DSS-induced Colitis Mice.

Cai L, Li X, Geng C, Lei X, Wang C.

Am J Physiol Cell Physiol. 2018 Jul 18. doi: 10.1152/ajpcell.00199.2018. [Epub ahead of print]

PMID:
30020824
8.

5-ASA to sulfasalazine drug switch program in patients with ulcerative colitis.

Goldsmith JR, Waljee AK, George T, Brown A, Choe HM, Noureldin M, Bernstein SJ, Higgins PDR.

Am J Manag Care. 2018 Jul;24(8 Spec No.):SP303-SP308.

9.

Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?

Porter RJ, Andrews C, Brice DP, Durum SK, McLean MH.

Inflamm Bowel Dis. 2018 Jul 18. doi: 10.1093/ibd/izy230. [Epub ahead of print]

PMID:
30020451
10.

[Effect of cystatin from Schistosoma japonicum on DSS - induced ulcerative colitis in mice].

Liang C, Hui-Hui L, Shu-Shu W, Yuan Y, Hui J, Lan-Song X, Wen-Xin H, Shou-Xiang W, Mu-Zi Z, Yong-Sheng B, Ming W, Tao L, Jie S, Xing-Zhi C, Qiang F, Xiao-di Y.

Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2018 May 29;30(3):269-272. doi: 10.16250/j.32.1374.2017193. Chinese.

PMID:
30019552
11.

The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series.

Russi L, Scharl M, Rogler G, Biedermann L.

Inflamm Intest Dis. 2017 Nov;2(2):131-138. doi: 10.1159/000481400. Epub 2017 Oct 19.

PMID:
30018964
12.

The Impact of Cold Spells on the Incidence of Infectious Gastroenteritis and Relapse Rates of Inflammatory Bowel Disease: A Retrospective Controlled Observational Study.

Manser CN, Kraus A, Frei T, Rogler G, Held L.

Inflamm Intest Dis. 2017 Nov;2(2):124-130. doi: 10.1159/000477807. Epub 2017 Jul 15.

PMID:
30018963
13.

Gut Microbiome in Inflammatory Bowel Disease and Other Chronic Immune-Mediated Inflammatory Diseases.

Bernstein CN, Forbes JD.

Inflamm Intest Dis. 2017 Nov;2(2):116-123. doi: 10.1159/000481401. Epub 2017 Oct 20. Review.

PMID:
30018962
14.

Epidemiology of Inflammatory Bowel Disease in India: The Great Shift East.

Kedia S, Ahuja V.

Inflamm Intest Dis. 2017 Nov;2(2):102-115. doi: 10.1159/000465522. Epub 2017 Apr 8. Review.

PMID:
30018961
15.

How Does the Epidemiology of Inflammatory Bowel Disease Differ between East and West? A Korean Perspective.

Yang SK.

Inflamm Intest Dis. 2017 Nov;2(2):95-101. doi: 10.1159/000454712. Epub 2017 Jan 14. Review.

PMID:
30018960
16.

Qualitative and Quantitative Characteristics of Selected Bacterial Groups in Children with Inflammatory Bowel Diseases.

Roszak D, Gałęcka M, Cichy W, Szachta P.

Pol J Microbiol. 2016 Jun 7;65(2):219-224. doi: 10.5604/17331331.1204483.

17.

Defining Failure of Medical Therapy for Inflammatory Bowel Disease.

Volk N, Siegel CA.

Inflamm Bowel Dis. 2018 Jul 16. doi: 10.1093/ibd/izy238. [Epub ahead of print]

PMID:
30016434
18.

Plasma Nuclear Magnetic Resonance metabolomics discriminates between high and low endoscopic activity and predicts progression in a prospective cohort of patients with ulcerative colitis.

Probert F, Walsh A, Jagielowicz M, Yeo T, Claridge TDW, Simmons A, Travis S, Anthony DC.

J Crohns Colitis. 2018 Jul 17. doi: 10.1093/ecco-jcc/jjy101. [Epub ahead of print]

PMID:
30016408
19.

Ulcerative colitis in an infant aged 20 months. A case report.

Wilczyńska D, Mielniczuk K, Szaflarska-Popławsk A, Krogulska A.

Arch Argent Pediatr. 2018 Aug 1;116(4):e599-e602. doi: 10.5546/aap.2018.eng.e599. English, Spanish.

20.

MicroRNA‑449a is a potential predictor of colitis‑associated colorectal cancer progression.

Feng Y, Dong YW, Song YN, Xiao JH, Guo XY, Jiang WL, Lu LG.

Oncol Rep. 2018 Jul 12. doi: 10.3892/or.2018.6566. [Epub ahead of print]

PMID:
30015944

Supplemental Content

Loading ...
Support Center